Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.

TL1A is encoded by TNFSF15 and is produced by endothelial cells. 5 Expression of TL1A can be induced in endothelial cells and chondrocytes under the influence of the inflammatory cytokines TNF and ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic inflammatory disease of the large intestine.

Ulcerative colitis (UC) is a chronic disease that causes inflammation in the large intestine, affecting between 600,000 and ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the ...

Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO. My name is Adam and I'll be your operator today. [Operator Instructions] I will now ...

It is also the first and only randomized, blinded and placebo-controlled phase 2 study to investigate the impact of TL1A in CD. In the study, patients who met pre-specified inclusion criteria were ...

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...

a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease ...